Related Tags >> HIV/AIDS FDA Phase III Phase II

HIV/AIDS News

Most Popular HIV/AIDS Story

ALSO NOTED: GSK losing its grip on HIV market; Ranexa gets angina review; Start-up CRO takes flight;and much more...

November 20, 2007 — 7:59am ET

> Watch out, GlaxoSmithKline. The market for HIV drugs may be expanding, but it's shifting like the San Andreas Fault at the same time, and more than a handful of companies are poised to challenge... Read more...

HIV/AIDS Press Releases

T cell-based HIV vaccine candidate demonstrates positive results
New hope for HIV treatment: Cells exhausted from fighting HIV infection can be revitalized
New York City Mayor Bloomberg, Honorees Celebrate First Laboratory Solely Devoted to the Development of an AIDS Vaccine
Pfizer's Novel HIV/AIDS Treatment Selzentry (Maraviroc) Demonstrates Increased Efficacy Rate In Treatment-Naïve HIV Patients
FDA Approves Tibotec Therapeutics's PREZISTA Once-Daily as Part of Combination Therapy for Treatment-Naive Adults with HIV-1

Latest Headlines

ALSO NOTED: New vaccine/chemo combo effective in cancer study; Type 1 diabetes vaccine goes into human studies; and much more..
May 29, 2008
Panacos surges on HIV response data
March 6, 2008
ALSO NOTED: Sirtris, NCI collaborate on cancer models; Kylin expands in Indiana; and much more...
February 21, 2008
Idenix reports success in early-stage HIV drug trial
February 7, 2008
Scientists examine Selzentry's ability to stop HIV
January 30, 2008
Theratechnologies explores sale, other options
January 29, 2008
RNAi screening finds 273 proteins used by HIV
January 11, 2008
Trimeris to axe R&D ops in '08 restructuring
December 11, 2007
ALSO NOTED: CEO: Novartis plans big restructuring; Time notes advances in stem cells, genetics; MabThera trials produce positiv
December 11, 2007
ALSO NOTED: GSK losing its grip on HIV market; Ranexa gets angina review; Start-up CRO takes flight;and much more...
November 20, 2007
Theratechnologies reports positive Phase III results
October 1, 2007
FDA panel endorses Merck's new AIDS drug
September 6, 2007
ALSO NOTED: Medicure raises $40M; FDA wants more data on Creon; Genta launches Phase III; and much more...
August 21, 2007
Tobira garners $31M to advance HIV drugs
August 2, 2007
Merck agrees on $308M deal for delivery platform
June 27, 2007
Gilead touts Phase III Hep B results
June 25, 2007
GSK drops out of Vertex pact for HIV therapy
December 17, 2006
Ambrilia inks $232M licensing deal of HIV drug
October 11, 2006
Vertex refines terms on $300M public offering
September 14, 2006
Scientists find that HIV drug attacks HPV virus
August 24, 2006

Paid Research Reports